Drug Therapy

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, The Cleveland Clinic

Address: Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail [email protected]

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.

William E. Braun, MD
Department of Nephrology and Hypertension, The Cleveland Clinic

Address: William E. Braun, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

This paper discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still investigational.

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Mark E. Dunlap, MD
Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center, Cleveland, Ohio

Ross C. Peterson, MD
University Hospitals of Cleveland and Louis Stokes VA Medical Center, Cleveland, Ohio

Address: Mark E. Dunlap, MD, Cleveland VA Medical Center, Research Service 151 W, 10701 East Boulevard, Cleveland, OH 44106; e-mail [email protected]

Dr. Dunlap has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Susan J. Rehm, MD
Department of Infectious Diseases, The Cleveland Clinic

Address: Susan J. Rehm, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Rehm has indicated that she has received grant or research support from the Aventis corporation and serves as a consultant and is on the speakers’ bureaus of the Pharmacia and Aventis corporations.

Susan J. Rehm, MD
Department of Infectious Diseases, The Cleveland Clinic

Address: Susan J. Rehm, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Rehm has indicated that she has received grant or research support from the Aventis corporation and serves as a consultant and is on the speakers’ bureaus of the Pharmacia and Aventis corporations.

Susan J. Rehm, MD
Department of Infectious Diseases, The Cleveland Clinic

Address: Susan J. Rehm, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Rehm has indicated that she has received grant or research support from the Aventis corporation and serves as a consultant and is on the speakers’ bureaus of the Pharmacia and Aventis corporations.

Maurie Markman, MD
Chairman, Taussig Cancer Center and Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Maurie Markman, MD, Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; email [email protected]

Maurie Markman, MD
Chairman, Taussig Cancer Center and Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Maurie Markman, MD, Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; email [email protected]

Maurie Markman, MD
Chairman, Taussig Cancer Center and Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Maurie Markman, MD, Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; email [email protected]